While preliminary, these findings encourage further research into the potential therapeutic benefits of this bioactive Bin1 MBD-targeting mAb to lower expression and deposition of phosphorylated tau, as a possible approach to treat AD and/or other tauopathies. Here, MAPT is linked to tauopathy.